Years after Pfizer Inc. dramatically discontinued the first CETP inhibitor torcetrapib – blowing a hole into a mechanism once hailed as the natural successor to the statins – Merck & Co. Inc. has breathed new life into the hypothesis by proving a cardiovascular outcomes advantage for its anacetrapib in the 30,000-patient REVEAL trial.
Merck announced June 27 that the CVOT study had met its primary endpoint, significantly reducing major coronary events (a composite...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)